Literature DB >> 10196450

Axonal cytoskeleton changes in experimental optic neuritis.

B Zhu1, G R Moore, T J Zwimpfer, L F Kastrukoff, J K Dyer, J D Steeves, D W Paty, M S Cynader.   

Abstract

Axonal loss and degeneration in multiple sclerosis (MS) and experimental allergic encephalomyelitis (EAE) have been suggested by brain imaging, pathological and axonal transport studies. Further elucidation of the processes and mechanisms of axonal degeneration in demyelinating diseases is therefore of potential importance in order to alleviate the permanent disabilities of MS patients. However, detailed studies in this area are impeded by the small number of reliable models in which the onset and location of demyelination can be well-controlled. In this study, microinjection of polyclonal rabbit anti-galactocerebroside (anti-Gal C) antibody and guinea pig complement was used to induce local demyelination in the rat optic nerve. We found that treatment with appropriate volumes of the antibody and complement could induce local demyelination with minimal pressure- or trauma-induced damage. Local changes in neurofilaments (NFs) and microtubules (MTs) were examined with both immunohistochemistry (IHC) and electron microscopy (EM). On day 1 after microinjection, we observed moderate NF and MT disassembly in the local demyelinated area, although in most cases, no apparent inflammatory cell infiltration was seen. The NF and MT changes became more apparent on days 3, 5, 7 after microinjection, along with gradually increased inflammatory cell infiltration. These results suggested that acute demyelination itself may induce local cytoskeleton changes in the demyelinated axons, and that the ensuing local inflammation may further enhance the axonal damage. When the lesions were stained with specific antibodies for T lymphocytes, macrophages, and astrocytes, we found that most of the cells were macrophages, suggesting that macrophages may play a greater role in inflammation-related axonal degeneration and axonal loss. These results were confirmed and further characterized on the ultrastructural level. Copyright 1999 Elsevier Science B.V.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10196450     DOI: 10.1016/s0006-8993(99)01191-9

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  4 in total

1.  New developments in the treatment of optic neuritis.

Authors:  Thomas M Jenkins; Ahmed T Toosy
Journal:  Eye Brain       Date:  2010-06-17

Review 2.  Translational research in neurology and neuroscience 2010: multiple sclerosis.

Authors:  Olaf Stüve; Bernd C Kieseier; Bernhard Hemmer; Hans-Peter Hartung; Amer Awad; Elliot M Frohman; Benjamin M Greenberg; Michael K Racke; Scott S Zamvil; J Theodore Phillips; Ralf Gold; Andrew Chan; Uwe Zettl; Ron Milo; Ellen Marder; Omar Khan; Todd N Eagar
Journal:  Arch Neurol       Date:  2010-07-12

3.  Does time equal vision in the acute treatment of a cohort of AQP4 and MOG optic neuritis?

Authors:  Hadas Stiebel-Kalish; Mark Andrew Hellmann; Michael Mimouni; Friedemann Paul; Omer Bialer; Michael Bach; Itay Lotan
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-05-21

Review 4.  Case for a new corticosteroid treatment trial in optic neuritis: review of updated evidence.

Authors:  Axel Petzold; Tasanee Braithwaite; Bob W van Oosten; Lisanne Balk; Elena H Martinez-Lapiscina; Russell Wheeler; Nils Wiegerinck; Christiaan Waters; Gordon T Plant
Journal:  J Neurol Neurosurg Psychiatry       Date:  2019-11-18       Impact factor: 10.154

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.